Cardiopulmonary Exercise Testing, Impedance Cardiography, and Reclassification of Risk in Patients Referred for Heart

Jonathan Myers1, Jeffrey W Christle2, Amanda Tun1

  • 1VA Palo Alto Health Care System, Division of Cardiovascular Medicine, Palo Alto, California; Stanford University, Stanford California.

Insights

Impedance cardiography (ICG) combined with cardiopulmonary exercise testing (CPX) significantly improves risk assessment for adverse events in heart failure (HF) patients. This approach enhances prediction beyond traditional CPX measures alone.

Area of Science:

  • Cardiology
  • Exercise Physiology
  • Medical Technology

Background:

  • Impaired cardiac output response to exercise is a key indicator of chronic heart failure (HF).
  • Accurate risk stratification is crucial for managing HF patients and predicting adverse outcomes.

Purpose of the Study:

  • To evaluate if impedance cardiography (ICG) during exercise, combined with cardiopulmonary exercise test (CPX) responses, can reclassify risk for adverse events in HF patients.
  • To determine the added value of noninvasive hemodynamic data from ICG to established CPX risk markers.

Main Methods:

  • 1236 patients evaluated for HF underwent CPX and ICG during exercise.
  • Clinical, ICG, and CPX variables were analyzed for association with a composite outcome (cardiac death, HF hospitalization, transplant, LVAD).
  • Cox proportional hazards analyses and Net Reclassification Improvement (NRI) were used to assess risk prediction and reclassification.

Main Results:

  • Peak VO2, VE/VCO2 slope, and oxygen uptake efficiency slope from CPX were significant risk predictors.
  • Changes in cardiac index, cardiac time interval, and left cardiac work index from ICG were also strong predictors.
  • Combining impaired CPX and ICG responses indicated a sevenfold higher risk of adverse events.
  • Adding ICG responses to CPX models resulted in significant NRIs (0.34-0.89), demonstrating improved risk reclassification.

Conclusions:

  • Cardiac hemodynamics assessed by ICG provide valuable information that complements CPX measures.
  • ICG enhances the reclassification of risk for adverse events in patients with heart failure.
  • The combination of ICG and CPX offers a more comprehensive approach to risk stratification in HF.
Abstract

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
324
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
768
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
720
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
273
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
821